Upadacitinib
Who holds supplier records for Upadacitinib? 11 organisations hold a current record for Upadacitinib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (4), China (4) and Spain (1); not recorded for 2.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Upadacitinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/upadacitinib
Reading the evidence
- 11 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 6 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Upadacitinib expires 9 Mar 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (11)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Upadacitinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 38095 · latest filing Feb 2023
- CHANGZHOU PHARMACEUTICAL FACTORYChina Company GMP cert on recordActive DMF 40355 · latest filing Aug 2024
- CRYSTAL PHARMACEUTICAL SUZHOU CO LTDActive DMF 38427 · latest filing Jun 2023
- CURIA SPAIN SAUSpain Company GMP cert on recordActive DMF 37149 · latest filing Jun 2022
- HEBEI CHENGUANG TONGSHENG PHARMA CO LTDChinaActive DMF 44634 · latest filing Aug 2026
- HOSTER LABS PRIVATE LTDIndia Company GMP cert on recordActive DMF 38344 · latest filing May 2023
- LEE PHARMA LTDIndia Company GMP cert on recordActive DMF 39581 · latest filing Mar 2024
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 38153 · latest filing Mar 2023
- Shanghai Desano Chemical Pharmaceutical Co., LtdChinaActive DMF 43571 · latest filing Feb 2026
- SICHUAN GOWELL PHARMACEUTICAL CO LTDActive DMF 40344 · latest filing Aug 2024
- Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.ChinaActive DMF 44747 · latest filing Sept 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Upadacitinib). The latest listed patent expires 9 Mar 2038. The latest listed exclusivity runs to 28 Apr 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Upadacitinib is an oral Janus kinase (JAK) inhibitor used for the treatment of several autoimmune disorders. It helps in reducing inflammation by targeting specific pathways involved in the inflammatory response.
Chemical identity
- IUPAC name
- (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
- Canonical SMILES
- CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
- InChIKey
- WYQFJHHDOKWSHR-MNOVXSKESA-N
- Synonyms
- Rinvoq API, abbv-599 component upadacitinib, abt-494, upadacitinib anhydrous
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Janus Kinase Inhibitor
- Mechanism of action
- Janus Kinase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Upadacitinib?
11 organisations hold an active US FDA Type II Drug Master File or a CEP for Upadacitinib: APITORIA PHARMA PRIVATE LTD (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), CRYSTAL PHARMACEUTICAL SUZHOU CO LTD, CURIA SPAIN SAU (Spain), HEBEI CHENGUANG TONGSHENG PHARMA CO LTD (China), HOSTER LABS PRIVATE LTD (India), LEE PHARMA LTD (India) and MSN Laboratories Private Limited (India), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Upadacitinib Drug Master Files are active?
APITORIA PHARMA PRIVATE LTD (DMF 38095), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 40355), CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (DMF 38427), CURIA SPAIN SAU (DMF 37149), HEBEI CHENGUANG TONGSHENG PHARMA CO LTD (DMF 44634), HOSTER LABS PRIVATE LTD (DMF 38344), LEE PHARMA LTD (DMF 39581) and MSN Laboratories Private Limited (DMF 38153) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Upadacitinib?
Yes. The latest patent listed for an approved US product containing Upadacitinib expires 9 Mar 2038, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Upadacitinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Upadacitinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.